Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: A critical appraisal and comprehensive review

British Journal of Dermatology

Volumn 170, Issue 1, 2014, Pages 20-30

  Fong, Z V ^a   Tanabe, K K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; PEGINTERFERON;

AUSTRALIA AND NEW ZEALAND; CANADA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; CONSENSUS; DRUG MEGADOSE; EUROPE; FOLLOW UP; HUMAN; IN-TRANSIT METASTASIS; LOW DRUG DOSE; MEDICAL SOCIETY; MELANOMA; METASTASIS RESECTION; ONCOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR BIOPSY; UNITED STATES; WIDE EXCISION; ANAMNESIS; AUSTRALIA; BIOPSY; EARLY DIAGNOSIS; LONG TERM CARE; METASTASIS; MULTIMODALITY CANCER THERAPY; NEW ZEALAND; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; SKIN NEOPLASMS;

AUSTRALIA; BIOPSY; CANADA; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; EUROPE; HUMANS; LONG-TERM CARE; MEDICAL HISTORY TAKING; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; NEW ZEALAND; PRACTICE GUIDELINES AS TOPIC; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; UNITED STATES;

EID: 84892399024     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12687     Document Type: Review

References (78)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Guy GP, Ekwueme DU,. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 2011; 29: 863-74.
3. Crowson AN, Magro CM, Mihm MC,. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol 2006; 19 (Suppl. 2): S71-87.
4. Balch CM, Gershenwald JE, Soong SJ, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
5. Tsao H, Atkins MB, Sober AJ,. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.
6. Ivry GB, Ogle CA, Shim EK,. Role of sun exposure in melanoma. Dermatol Surg 2006; 32: 481-92.
7. Waldmann A, Nolte S, Weinstock MA, et al,. Skin cancer screening participation and impact on melanoma incidence in Germany-an observational study on incidence trends in regions with and without population-based screening. Br J Cancer 2012; 106: 970-4.
8. National Ccomprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Available at: http://www.nccn.org/ professionals/physician-gls/pdf/melanoma.pdf (last accessed 24 September 2013).
9. Dummer R, Hauschild A, Guggenheim M, et al,. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): v194-7.
10. Australian Cancer Network and New Zealand Guidelines Group. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Available at: http://www.nhmrc.gov.au/-files-nhmrc/publications/attachments/ cp111.pdf (last accessed 24 September 2013).
11. Aitken JF, Janda M, Elwood M, et al,. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol 2006; 54: 105-14.
12. Fritschi L, Dye SA, Katris P,. Validity of melanoma diagnosis in a community-based screening program. Am J Epidemiol 2006; 164: 385-90.
13. Burton RC, Howe C, Adamson L, et al,. General practitioner screening for melanoma: sensitivity, specificity, and effect of training. J Med Screen 1998; 5: 156-61.
14. Cancer Care Ontario. Screening for skin cancer. Available at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/ File%20Database/CCO%20Files/PEBC/pebc15-1s.pdf (last accessed 24 September 2013).
15. Smith RA, Cokkinides V, Eyre HJ,. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 2006; 56: 11-25, quiz 49-50.
16. Friedman RJ, Rigel DS, Silverman MK, et al,. Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin. CA Cancer J Clin 1991; 41: 201-26.
17. Schwartz JL, Wang TS, Hamilton TA, et al,. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002; 95: 1562-8.
18. Barr RJ, Linden KG, Rubinstein G, Cantos KA,. Analysis of heterogeneity of atypia within melanocytic nevi. Arch Dermatol 2003; 139: 289-92.
19. Martin RC 2nd, Scoggins CR, Ross MI, et al,. Is incisional biopsy of melanoma harmful? Am J Surg 2005; 190: 913-17.
20. Bong JL, Herd RM, Hunter JA,. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 2002; 46: 690-4.
21. Veronesi U, Cascinelli N, Adamus J, et al,. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159-62.
22. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al,. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0·8-2·0 mm. Cancer 2000; 89: 1495-501.
23. Khayat D, Rixe O, Martin G, et al,. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2·1-mm thick). Cancer 2003; 97: 1941-6.
24. Thomas JM, Newton-Bishop J, A'Hern R, et al,. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-66.
25. Gillgren P, Drzewiecki KT, Niin M, et al,. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011; 378: 1635-42.
26. Haigh PI, DiFronzo LA, McCready DR,. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003; 46: 419-26.
27. Thompson JF, Uren RF,. Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncol 2005; 6: 877-85.
28. Gershenwald JE, Colome MI, Lee JE, et al,. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253-60.
29. Gershenwald JE, Thompson W, Mansfield PF, et al,. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-83.
30. Faries MB, Thompson JF, Cochran A, et al,. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010; 17: 3324-9.
31. Morton DL, Thompson JF, Cochran AJ, et al,. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-17.
32. Morton DL, Cochran AJ, Thompson JF,. The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol 2008; 5: 510-11.
33. Andtbacka RH, Gershenwald JE,. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw 2009; 7: 308-17.
34. Ferrone CR, Panageas KS, Busam K, et al,. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002; 9: 637-45.
35. Gershenwald JE, Mansfield PF, Lee JE, Ross MI,. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥ 4 mm) primary melanoma. Ann Surg Oncol 2000; 7: 160-5.
36. Cancer Care Ontario. Primary excision margins and sentinel lymph node biopsy in clinically node-negative cutaneous melanoma of the trunk or extremities. Available at: https://www.cancercare.on.ca/common/pages/UserFile. aspx?fileId=73874 (last accessed 24 September 2013).
37. Grob JJ, Dreno B, de la Salmoniere P, et al,. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351: 1905-10.
38. Pehamberger H, Soyer HP, Steiner A, et al,. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 1425-9.
39. Cascinelli N, Belli F, MacKie RM, et al,. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358: 866-9.
40. Eggermont AM, Suciu S, MacKie R, et al,. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189-96.
41. Kirkwood JM, Strawderman MH, Ernstoff MS, et al,. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
42. Kirkwood JM, Ibrahim JG, Sondak VK, et al,. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-58.
43. Eggermont AM, Suciu S, Santinami M, et al,. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-26.
44. Cancer Care Ontario. Systemic adjuvant therapy for patients at high risk for recurrent melanoma. Available at: https://www.cancercare.on.ca/common/pages/ UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc8-1s. pdf (last accessed 24 September 2013).
45. Agrawal S, Kane JM 3rd, Guadagnolo BA, et al,. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 115: 5836-44.
46. Burmeister BH, Henderson MA, Ainslie J, et al,. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13: 589-97.
47. Stevens G, Thompson JF, Firth I, et al,. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000; 88: 88-94.
48. Burmeister BH, Mark Smithers B, Burmeister E, et al,. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96·06. Radiother Oncol 2006; 81: 136-42.
49. Carlson JA, Dickersin GR, Sober AJ, Barnhill RL,. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer 1995; 75: 478-94.
50. Livestro DP, Muzikansky A, Kaine EM, et al,. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol 2005; 23: 6739-46.
51. Chen JY, Hruby G, Scolyer RA, et al,. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008; 113: 2770-8.
52. Roses DF, Harris MN, Rigel D, et al,. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983; 198: 65-9.
53. Pawlik TM, Ross MI, Johnson MM, et al,. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12: 587-96.
54. Tan JK, Ho VC,. Pooled analysis of the efficacy of bacille Calmette-Guérin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993; 19: 985-90.
55. Hill S, Thomas JM,. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996; 83: 509-12.
56. Wolf IH, Richtig E, Kopera D, Kerl H,. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg 2004; 30: 244-7.
57. Steinmann A, Funk JO, Schuler G, von den Driesch P,. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000; 43: 555-6.
58. Lens MB, Dawes M,. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol 2003; 4: 359-64.
59. Thompson JF, Kam PC,. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004; 88: 1-3.
60. Boesch CE, Meyer T, Waschke L, et al,. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. Int J Hyperthermia 2010; 26: 16-20.
61. Beasley GM, Caudle A, Petersen RP, et al,. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009; 208: 706-15; discussion 715-17.
62. Buzaid AC, Ross MI, Balch CM, et al,. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15: 1039-51.
63. Hodi FS, O'Day SJ, McDermott DF, et al,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
64. Robert C, Thomas L, Bondarenko I, et al,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
65. Weber JS, Kahler KC, Hauschild A,. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-7.
66. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
67. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF,. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88: 11-20.
68. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al,. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999; 44: 607-18.
69. Olivier KR, Schild SE, Morris CG, et al,. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 2007; 110: 1791-5.
70. Romano E, Scordo M, Dusza SW, et al,. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010; 28: 3042-7.
71. Francken AB, Bastiaannet E, Hoekstra HJ,. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6: 608-21.
72. Ferrone CR, Ben Porat L, Panageas KS, et al,. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005; 294: 1647-54.
73. Dicker TJ, Kavanagh GM, Herd RM, et al,. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999; 140: 249-54.
74. Francken AB, Shaw HM, Accortt NA, et al,. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14: 1924-33.
75. Machet L, Nemeth-Normand F, Giraudeau B, et al,. Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients. Br J Dermatol 2005; 152: 66-70.
76. Boni A, Cogdill AP, Dang P, et al,. Selective BRAF V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213-19.
77. Poulikakos PI, Persaud Y, Janakiraman M, et al,. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-90.
78. Fong ZV, Winter JM,. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J 2012; 18: 530-8.